8-K: Microbot Medical Reports Q2 Revenue Exceeds Q1 Amid LIBERTY System Rollout

Microbot Medical Inc. announced that its second quarter 2026 revenue has already surpassed first quarter revenue, driven by the accelerated utilization and adoption of its LIBERTY Endovascular Robotic System following its full market release.

Summary

• Microbot Medical Inc. has announced that its revenue for the second quarter of 2026 has already exceeded the total revenue from the first quarter of 2026.
• This increase is attributed to the company's transition from a limited market release to a full market release of its LIBERTY Endovascular Robotic System.
• The utilization and adoption of the LIBERTY System are accelerating across multiple sales territories.
• The number of accounts using the LIBERTY system has more than doubled since the end of the limited market release.
• Hospitals in six states (Georgia, Florida, New York, Michigan, Massachusetts, and North Carolina) have adopted the system.
• Boston, Massachusetts, is the first city with multiple accounts using the LIBERTY system.
• The system has been used for various procedures including robotic Prostatic Artery Embolization (PAE), robotic Genicular Artery Embolization (GAE) for knee pain, and robotic Y-90 radioembolization for liver cancer.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with strong revenue growth and market adoption exceeding initial expectations, signaling successful commercialization.

Positives

• Second quarter 2026 revenue has already exceeded first quarter 2026 revenue.
• The number of accounts using the LIBERTY system has more than doubled since the limited market release.
• The LIBERTY System is being adopted across six states, indicating expanding market penetration.
• The company is experiencing an increase in recurring customer orders.
• New territories launched in early April have already secured accounts, validating the commercial strategy.
• The LIBERTY System has been utilized for novel procedures, including the world's first robotic Prostatic Artery Embolization (PAE) and robotic Genicular Artery Embolization (GAE).

Risks

• Actual results could differ from forward-looking statements due to numerous factors.
• The company assumes no obligation to update forward-looking statements except as required by law.
• There can be no assurance that beliefs, plans, expectations, or intentions will prove to be accurate.
• Investors should refer to risk factors disclosed in the company's periodic reports filed with the SEC.
• Risks include market conditions, commercialization of the LIBERTY System, development of future versions, regulatory pathways and approvals, political/social/geopolitical conditions, FDA personnel/process changes, import tariffs, and ongoing hostilities in the Middle East.

Future Outlook

The company expects commercial adoption to accelerate due to value-enhancing developments like updated guidelines on occupational radiation and musculoskeletal protection, and continued visibility at major conferences. These factors are expected to support continued U.S. commercial adoption and facilitate global commercial infrastructure growth.

Management Comments

• "Our success during the first quarter was demonstrated across multiple metrics, including the continued progress of the limited market release leading to us commence the Full Market Release, the number of accounts that adopted the LIBERTY system and the users that deployed it for varied procedures."
• "Our momentum so far during the second quarter is encouraging and reinforces our confidence as we have more than doubled the number of accounts and expanded our footprint into several new cities and states since the commencement of the Full Market Release."
• "Additionally, we believe that customer enthusiasm and satisfaction remain high, supported by recurring orders to support procedures over the coming weeks and months."
• "Our newest territories in the Midwest and Mid-Atlantic, which were launched in early April, have already secured accounts, further validating our commercial execution strategy, and it emboldens the team as we continue to roll out the commercial strategy to penetrate population-rich regions in the U.S. in the second half of the year along with commercial readiness activities in international markets."

Industry Context

StockSavvy.ai notes that Microbot Medical's announcement aligns with a broader trend in the medical device industry towards robotic-assisted procedures, aiming to improve precision, efficiency, and patient outcomes. The company's focus on endovascular robotics addresses a growing demand for minimally invasive treatments.

Stakeholder Impact

• Shareholders: Potential for increased valuation and return on investment due to strong revenue growth and market adoption.
• Customers (Hospitals/Physicians): Access to an innovative robotic system that enables new and advanced endovascular procedures, potentially improving patient care and procedural efficiency.
• Employees: Positive impact from company growth and success, potentially leading to increased opportunities and job security.

Next Steps

• Continue to roll out the commercial strategy to penetrate population-rich regions in the U.S. in the second half of the year.
• Undertake commercial readiness activities in international markets.
• Leverage updated guidelines on occupational radiation and musculoskeletal protection to drive adoption.
• Maintain visibility at major conferences such as SIR and the upcoming Annual Global Embolization Symposium & Technologies (GEST) Conference.

Key Dates

Recommendation

The company is showing strong positive momentum with revenue exceeding expectations and market adoption accelerating. However, the filing is primarily an update on commercial progress and does not contain new financial guidance or significant strategic shifts that would warrant a stronger buy/sell recommendation at this juncture. Further analysis of profitability and long-term growth sustainability is needed.

Keywords

Microbot Medical, LIBERTY Endovascular Robotic System, Robotic Surgery, Medical Device, Endovascular Procedures, Revenue Growth, Commercial Release, Healthcare Technology